

Chronic Obstructive Pulmonary Disease: Improving Control of Symptoms and Optimizing Patient Outcomes

ICHHP 2013 Annual Meeting

ACPE#: 0204-0000-13-448-L01-P **Credit Hours:** 1.0
Date: Friday, September 20, 2013
Time: 12:15pm – 1:15pm
Location: Drury Lane Theatre and Conference Center, Oakbrook Terrace, IL

Activity Description

This activity will provide an overview of the incidence, clinical course, morbidity, and mortality associated with chronic obstructive pulmonary disease (COPD). Because there is no cure for COPD, strategies that control symptoms and prevent disease progression are important. In addition, minimizing exacerbations is a major goal of treatment. The role of pharmacists in managing patients with COPD will be described, including the use of emerging treatment options.

Patient scenarios will be included throughout the presentation, and there will be time for questions and answers at the end.

Learning Objectives

After attending this application-based educational activity, participants should be able to

- Outline the incidence, mortality, and morbidity of chronic obstructive pulmonary disease (COPD) in the United States.
- Apply current evidence-based guidelines for managing patients with COPD in order to meet management goals.
- Examine emerging treatment options for the management of COPD.
- Incorporate at least one strategy for improving outcomes for patients with COPD into practice.

Continuing Education Information



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 1 hour (0.1 CEU) of continuing pharmacy education credit (ACPE Activity #0204-0000-13-448-L01-P).

Attendees must complete a Continuing Pharmacy Education Request online and may immediately print their statements of continuing pharmacy education credit at the ASHP eLearning site (elearning.ashp.org).

Faculty

Dennis M. Williams, Pharm.D., BCPS, AE-C, FASHP, FCCP, FAPhA
Associate Professor and Vice Chair
Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy
University of North Carolina
Chapel Hill, North Carolina

This activity is planned and conducted by ASHP Advantage and supported by an educational grant from AstraZeneca and an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.